Drugs / RN1701
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07563543 | May 2026 → May 2028 expected | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07316920 | Dec 2025 → Jun 2027 expected | B-cell non-Hodgkin lymphoma | YANRU WANG | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07506668 | Mar 2026 → Mar 2028 expected | B-cell non-Hodgkin lymphoma | Affiliated Hospital of Nantong University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RN1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07506668 ↗ |
| Known as | RN1701 injection | “RN1701 injection is a bispecific CD19/CD20-targeted allogeneic CAR-T.” NCT07506668 ↗ |
| Action | Deplete | “ability of RN1701 to deplete CD19- and/or CD20-positive cells” NCT07316920 ↗ |
| Modality | Cell therapy | “RN1701 injection is a bispecific CD19/CD20-targeted allogeneic CAR-T.” NCT07316920 ↗ |
| Route | Intravenous | “administered intravenously” NCT07316920 ↗ |